Dr.Reddy’s launches two generic drugs in U.S.

Pharma major Dr.Reddy’s Laboratories Ltd. on Wednesday announced the launch of the generic versions — an anti-depressant and muscle relaxant — in the U.S.

Bupropion Hydrochloride Extended-Release Tablets, the anti-depressant launched by the Hyderabad-headquartered firm, is a therapeutic equivalent of the generic version of GlaxoSmithKline’s Wellbutrin XL tablets.

The Wellbutrin XL brand and generic had U.S. sales of around $754 million MAT for the 12 months ended July 2017, Dr.Reddy’s said citing IMS Health figures.

The Bupropion Hydrochloride Extended-Release tablets, USP (XL), 150 mg and 300 mg, are available in bottle count sizes of 30, 90 and 500, a release from DRL said.

In a separate announcement, the company said it has launched Metaxalone tablets, a therapeutic equivalent generic version of Skelaxin (metaxalone) tablets.

A muscle relaxant, Skelaxin is z trademark of King Pharmaceuticals Research and Development Inc.

According to Dr.Reddy’s, the Skelaxin brand and generic, as per IMS Health, had sales of approximately $139 million MAT in the U.S. during the twelve months ended July 2017.

The Metaxalone Tablets, USP 800 mg are available in the bottle count size of 100, a release from DRL said.